Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Treatable traits in the NOVELTY study: assessing complexity by network analysis

Rosa Faner, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Alvar Agustí
European Respiratory Journal 2021 58: OA1593; DOI: 10.1183/13993003.congress-2021.OA1593
Rosa Faner
1IDIBAPS, Centro de Investigación Biomedica en Red M.P, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: RFANER@clinic.cat
Eleni Rapsomaniki
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Beasley
3Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rod Hughes
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana Müllerová
2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Papi
4Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian D Pavord
5Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agustí
6Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 58 no. suppl 65
DOI 
https://doi.org/10.1183/13993003.congress-2021.OA1593

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online November 25, 2021.

Copyright & Usage 
Copyright ©the authors 2021

Author Information

  1. Rosa Faner1⇑,
  2. Eleni Rapsomaniki2,
  3. Richard Beasley3,
  4. Rod Hughes2,
  5. Hana Müllerová2,
  6. Alberto Papi4,
  7. Ian D Pavord5 and
  8. Alvar Agustí6
  1. 1IDIBAPS, Centro de Investigación Biomedica en Red M.P, Barcelona, Spain
  2. 2BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
  3. 3Medical Research Institute of New Zealand, Wellington, New Zealand
  4. 4Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy
  5. 5Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  6. 6Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
  1. Rosa Faner, IDIBAPS, Centro de Investigación Biomedica en Red M.P, Barcelona, Spain. E-mail: RFANER{at}clinic.cat

Article usage

Article usage: November 2021 to December 2022

AbstractFullPdf
Nov 20214200
Dec 20219100
Jan 202211800
Feb 20221900
Mar 20221800
Apr 20222700
May 20221600
Jun 20222400
Jul 20222300
Aug 20221400
Sep 20221000
Oct 20223200
Nov 20222100
Dec 2022900

Altmetrics

Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatable traits in the NOVELTY study: assessing complexity by network analysis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treatable traits in the NOVELTY study: assessing complexity by network analysis
Rosa Faner, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Alvar Agustí
European Respiratory Journal Sep 2021, 58 (suppl 65) OA1593; DOI: 10.1183/13993003.congress-2021.OA1593

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Treatable traits in the NOVELTY study: assessing complexity by network analysis
Rosa Faner, Eleni Rapsomaniki, Richard Beasley, Rod Hughes, Hana Müllerová, Alberto Papi, Ian D Pavord, Alvar Agustí
European Respiratory Journal Sep 2021, 58 (suppl 65) OA1593; DOI: 10.1183/13993003.congress-2021.OA1593
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Systemic interleukin-26 relates to the risk of exacerbations in smokers with COPD and chronic bronchitis
  • Oxygen therapy within first 24 hours of admission in patients with COPD and risk of adverse events - an observational study
  • Heterogeneity and time course of asthma exacerbations: data from AUSTRI
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society